Borgatti Antonella, Winter Amber L, Stuebner Kathleen, Scott Ruth, Ober Christopher P, Anderson Kari L, Feeney Daniel A, Vallera Daniel A, Koopmeiners Joseph S, Modiano Jaime F, Froelich Jerry
Animal Cancer Care and Research (ACCR) Program, College of Veterinary Medicine, University of Minnesota, St. Paul, Minnesota, United States of America.
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, Minnesota, United States of America.
PLoS One. 2017 Feb 21;12(2):e0172651. doi: 10.1371/journal.pone.0172651. eCollection 2017.
Positron Emission Tomography-Computed Tomography (PET-CT) is routinely used for staging and monitoring of human cancer patients and is becoming increasingly available in veterinary medicine. In this study, 18-fluorodeoxyglucose (18FDG)-PET-CT was used in dogs with naturally occurring splenic hemangiosarcoma (HSA) to assess its utility as a staging and monitoring modality as compared to standard radiography and ultrasonography. Nine dogs with stage-2 HSA underwent 18FDG-PET-CT following splenectomy and prior to commencement of chemotherapy. Routine staging (thoracic radiography and abdominal ultrasonography) was performed prior to 18FDG-PET-CT in all dogs. When abnormalities not identified on routine tests were noted on 18FDG-PET-CT, owners were given the option to repeat a PET-CT following treatment with eBAT. A PET-CT scan was repeated on Day 21 in three dogs. Abnormalities not observed on conventional staging tools, and most consistent with malignant disease based on location, appearance, and outcome, were detected in two dogs and included a right atrial mass and a hepatic nodule, respectively. These lesions were larger and had higher metabolic activity on the second scans. 18FDG-PET-CT has potential to provide important prognostic information and influence treatment recommendations for dogs with stage-2 HSA. Additional studies will be needed to precisely define the value of this imaging tool for staging and therapy monitoring in dogs with this and other cancers.
正电子发射断层扫描-计算机断层扫描（PET-CT）通常用于人类癌症患者的分期和监测，并且在兽医学中越来越普及。在本研究中，18-氟脱氧葡萄糖（18FDG）-PET-CT被用于患有自然发生的脾脏血管肉瘤（HSA）的犬，以评估其作为分期和监测方式与标准放射摄影和超声检查相比的效用。9只患有2期HSA的犬在脾切除术后且化疗开始前接受了18FDG-PET-CT检查。所有犬在进行18FDG-PET-CT检查之前均进行了常规分期（胸部放射摄影和腹部超声检查）。当在18FDG-PET-CT上发现常规检查未发现的异常时，给予犬主选择在接受eBAT治疗后重复进行PET-CT检查的机会。3只犬在第21天重复进行了PET-CT扫描。在2只犬中检测到了常规分期工具未观察到的异常，根据位置、外观和结果，这些异常最符合恶性疾病，分别包括右心房肿块和肝结节。这些病变在第二次扫描时更大且代谢活性更高。18FDG-PET-CT有潜力为患有2期HSA的犬提供重要的预后信息并影响治疗建议。需要进一步的研究来精确确定这种成像工具在患有这种癌症和其他癌症的犬的分期和治疗监测中的价值。
